Author:
Chitoran Elena,CIRIMBEI Ciprian,Simion Laurenţiu,Tănase B.,Ştefan Daniela-Cristina,Luca Dan Cristian,Rotaru V.
Reference21 articles.
1. Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. The Oncologist. 2007;12(4):443–50.
2. Pollack A. FDA Approves Cancer Drug from Genentech 27 February 2004. The New York Times. Archived 24 October 2016 at the Wayback Machine. Available at: https://www.nytimes.com/2004/02/27/business/fda-approves-cancer-drug-from-genentech.html
3. European Medicines Agency. Bevacizumab Scientific Discussion, 2005. Archived 24 September 2015 at the Wayback Machine.
4. Ribatti D. Napoleone Ferrara and the saga of vascular endothelial growth factor. Endothelium. 2008;15(1):1–8.
5. Palmer AM, Stephenson FA, Williams RJ. Society for Medicines Research: 40th anniversary symposium. Drug News & Perspectives. 2007 Apr;20(3):191–6.